These results indicated that KDM4A might serve as an AML treatment target similar to KDM4C and targeting KDM4s has the potential to significantly inhibit leukemia cells without killing normal human hematopoietic cells. The gene discussed is KDM4A; the disease is acute myeloid leukemia.